Pliant Therapeutics is advancing its lead candidate PLN-101095, an oral dual inhibitor targeting αvβ8 and αvβ1 integrins, demonstrating encouraging Phase 1 responses in immune checkpoint inhibitor-resistant solid tumors. While the company’s proprietary platform leverages integrin biology with translational screening technologies, it remains pre-revenue and faces typical biotech challenges including clinical setbacks such as trial discontinuation in fibrosis indications. Financials show a pattern of substantial but decreasing losses amid tightening capital management and cost control measures. Upcoming milestones include Phase 1b expansion and AACR presentations, yet regulatory and healthcare compliance burdens compound operational complexity in a highly competitive environment.